At a glance
ClinicalIndex Comparison RecordN/ACompleted· 88 enrolled
Drug / intervention
aprepitant +2 moredrug
Likely dose
aprepitant 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant
In Brief
A clinical study evaluating aprepitant, palonosetron, and 1 other intervention for Postoperative Nausea and Vomiting. Completed, enrolled 88 participants.
Detailed Summary
The purpose of this study was to compare the antiemetic efficacy of aprepitant plus palonosetron versus aprepitant plus ramosetron in high risk patients undergoing laparoscopic cholecystectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Nausea and Vomiting
Countries--
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJul 2014
Primary CompletionMay 2015
Study CompletionJul 2015
First PostedNov 2015
TodayJul 2026
First PostedNov 5, 2015
Enrollment StartJul 1, 2014
Primary CompletionMay 1, 2015
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.7 years ago
Interventions
aprepitantdrug
aprepitant 80 mg is given to all patients before surgery
palonosetrondrug
palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia
Ramosetrondrug
ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia